In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Max Bayer

Pharma Reporter

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for approving future Covid-19 vaccines …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Max Bayer

Pharma Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

RFK Jr. spars with senators over research cuts, HHS budget plan

CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Pharma Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines